Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Greencore and Bakkavor granted more time in £1.2bn takeover talks

(Sharecast News) - Greencore and Bakkavor have been granted more time to seal a £1.2bn takeover, the FTSE 250 convenience food makers confirmed on Friday. Pre-packed sandwich specialist Greencore announced in early April that it had agreed in principle a 200p per share deal to acquire Bakkavor, one of the UK's biggest makers of fresh convenience food.

Under Takeover Panel rules, Greencore had until 11 April to carry out due diligence before either making a formal offer or walking away, a so-called put up or shut up.

The deadline was then pushed back to 9 May, and has now been extended once more to 1700 BST on 23 May.

In a brief statement, issued with the consent of Greencore, Bakkavor said it had applied for the extension "to allow time to continue discussions with Greencore regarding the other terms and conditions of the possible offer, including completion of mutual confirmatory due diligence to the satisfaction of Greencore and Bakkavor".

It added that there was "no certainty any firm offer" would be made.

Should the cash and stock deal go ahead, it will create a market-leading food group with combined revenues of around £4bn. Bakkavor's customers include Tesco, Marks & Spencer and Waitrose.

The 200p offer price represents a 32.5% premium to Bakkavor's closing share price on 13 March. Bakkavor had previously rejected an earlier 189p per share offer from Greencore.

As at 0900 BST, shares in Greencore were up 1% at 191p, while Bakkavor was trading 2% higher at 186.36p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.